A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Stopped early · Phase 1/Phase 2
Conditions studied: ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
In brief
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
Key facts
- Study ID
- NCT05119335
- Run by
- NiKang Therapeutics, Inc.
- People needed
- 120
- Starts
- 2021-10-26
- Expected to finish
- 2025-09-30
- Last updated by the study team
- 2025-11-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- HonorHealth — Scottsdale, Arizona, United States
- UCLA — Los Angeles, California, United States
- Sarah Cannon Research Institute — Denver, Colorado, United States
- Emory University — Atlanta, Georgia, United States
- Indiana University Simon Comprehensive Cancer Center — Indianapolis, Indiana, United States
- University of Iowa — Iowa City, Iowa, United States
- National Cancer Institute — Bethesda, Maryland, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Nebraska Cancer Specialists — Omaha, Nebraska, United States
- University of Oklahoma — Oklahoma City, Oklahoma, United States
- Oregon Health and Science University — Portland, Oregon, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Seattle Cancer Care Alliance — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.